Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma Mary A. Maluccio, MD, MPH, Anne M. Covey, MD, Leah Ben Porat, PhD, Joanna Schubert, MD, Lynn A. Brody, MD, Constantinos T. Sofocleous, MD, George I. Getrajdman, MD, William Jarnagin, MD, Ronald DeMatteo, MD, Leslie H. Blumgart, MD, Yuman Fong, MD, Karen T. Brown, MD Journal of Vascular and Interventional Radiology Volume 19, Issue 6, Pages 862-869 (June 2008) DOI: 10.1016/j.jvir.2008.02.013 Copyright © 2008 SIR Terms and Conditions
Figure 1 Overall survival of patients with HCC who underwent TAE. Journal of Vascular and Interventional Radiology 2008 19, 862-869DOI: (10.1016/j.jvir.2008.02.013) Copyright © 2008 SIR Terms and Conditions
Figure 2 Overall survival of 159 patients with HCC without PV occlusion or extrahepatic disease (78 dead of disease). Median survival time was 40 months (95% CI, 31–52 months) and median follow-up for survivors was 27 months. Journal of Vascular and Interventional Radiology 2008 19, 862-869DOI: (10.1016/j.jvir.2008.02.013) Copyright © 2008 SIR Terms and Conditions